Ridsiewe may be a hot topic now, according tomedia BGR, as the antiviral drug, originally used to treat Ebola, will bring new standards of treatment to PATIENTs with COVID-19, according tomedia BGR. The drug may not prevent death, but preliminary results from a large-scale study suggest it can shorten recovery time in patients infected with the new coronavirus. Although COVID-19 complications still occur, the drug may help patients recover more quickly and reduce their hospital stay. This is of great help to both patients and the medical centers that treat large numbers of COVID-19 patients.
However, at present, there is no “magic medicine” for new coronapneumonia. Many scientists believe that vaccines are the “ultimate weapon” to solve the new pandemic. About 90 different vaccine candidates are currently under development. A new vaccine from Germany has just entered human trials and could reach millions of people as soon as this autumn. But that’s the kind of treatment that’s urgent, or not for the general population. Those who are on the front line to fight the disease, including doctors, nurses, police and other necessary personnel, will be the first to be vaccinated.
German company BioNTech has developed a COVID-19 vaccine called BNT162, and on April 23, the first 12 people were vaccinated in Germany. BioNTech has partnered with pharmaceutical giant Pfizer to expand the trial to U.S. volunteers who could get the drug as early as next week. Pfizer may prepare the drug for emergency use this fall.
“The two companies plan to conduct joint clinical trials of COVID-19 vaccine candidates, initially at multiple research sites in Europe and the United States,” Pfizer said in its first-quarter 2020 results earlier this week. “The companies estimate that if the development plan is technically successful and approved by regulators, it could provide millions of doses of vaccine by the end of 2020 and rapidly expand its capacity to produce hundreds of millions of doses by 2021. “
BioNTech plans to administer doses ranging from 1 microgram to 100 micrograms to 200 healthy volunteers between the ages of 18 and 55, CNN reported. The company not only evaluates the effectiveness and safety of the drug in the 1/2 phase study, but is also looking for the best dose of the drug. The report did not mention what type of vaccine BNT162 was, but a previous WHO listing revealed that BioNTech/Pfizer’s only vaccine was an mRNA drug that was still in the preclinical stage as of April 20. BioNTech and Pfizer’s announcement also confirmed that BNT162 is a mRNA vaccine.
Earlier this week, the journal Nature produced an illustration showing the differences between these vaccines. The above picture explains the gene vaccine, including RNA and DNA type gene vaccine.
BioNTech isn’t the only company that’s working on the mRNA vaccine, and it may be ready for emergency use by the fall. Moderna has asked for approval to begin phase 2 trials of its vaccine candidate, the first of its kind to be distributed to U.S. volunteers more than a month ago. Moderna also estimates that, assuming the vaccine is effective and safe, it could be used urgently this fall. In addition, researchers at Oxford University have previously said they are expected to develop a new coronavirus vaccine this fall.